2bind added CE-SDS and cIEF to its analytical service portfolio for antibody development

2bind is the premium partner for preclinical R&D biopharma services in Small Molecule Drug Discovery and early-stage Antibody Development. We support biotech and pharma innovators in discovering, validating, optimizing, and de-risking therapeutic molecules. For small molecule drug discovery, we offer end-to-end support—from protein purification and hit identification to hit validation, hit-to-lead and lead optimization—delivering high-quality data rapidly to enable fast and confident decision-making. For antibodies and other biologics, our robust and reliable workflows support screening, lead selection, developability assessment, binding and functional characterization, pre-formulation and storage stability studies. We empower our clients to enter costly development phases with confidence by providing the data for trusted risk assessment and design of appropriate mitigation strategies. Work with the fastest CRO in the world – to unlock the potential of your small molecule drug discovery. Work with the most trusted CRO – to proceed with your lead antibody with confidence.

Founded 2017